About one-third of patients with psoriasis are children or adolescents. Still, little research exists on treating this patient population. New disease management guidelines and emerging studies seek to fill the gap.
Treatments for Plaque Psoriasis
When George Martin, M.D., was doing his dermatology residency at UCLA in the mid-1980s, psoriasis was considered a disorder of keratinization.
Do you recommend psychotherapy to your psoriasis patients? While there is a well-established connection between psoriasis and mental health, there is little data available on the impact of psychological interventions on psoriasis. These study authors look to fill that gap.
There are more treatment options for psoriasis patients than ever before, so why do patient reported outcomes still suggest failure to meet patient expectations? Experts from the International Psoriasis Council (IPC) highlight factors that could be causing the perceived disparity between psoriasis treatment and patient satisfaction.
Psoriasis patients with skin of color experience psoriasis differently, often reporting worse health related quality of life outcomes compared to their Caucasian peers. Brodalumab may help, suggests a recent study.
The evaluation of psoriasis requires more than simply checking the severity and spread of the disease, a new report suggests. Rather, physicians should try to distinguish between stable and active disease with an eye toward the wider body-wide effects of the latter form.
Cognitive behavioral therapy (CBT) can successfully treat the physical symptoms of psoriasis and systemic treatment doesn't seem to provide an extra boost to its effectiveness, a new systematic review and meta-analysis finds.
In psoriasis, many therapies offer roughly the same level of care, but that doesn’t mean any patient will respond well to any therapy. According to Mark Lebwohl, M.D., physicians should consider each treatment option in light of a patient's specific comorbidities.
Why do biologics lose efficacy over time? This physician discusses factors dermatologists should consider when they see this issue in their patients.
Researchers found a significant inverse correlation between ustekinumab levels and PASI scores at week 52, suggesting that drug levels are associated with the change in the treatment response. Measuring ustekinumab levels can have major clinical implications.